Skip to main
EVAX
EVAX logo

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion has demonstrated a robust growth trajectory through its deepening partnership with Merck, which not only enhances its credibility but also provides financial backing for future innovations. The company has effectively built a versatile AI-Immunology platform that has resulted in a strong portfolio of preclinical and clinical candidates, positioning it for significant milestones in the near future. Additionally, recent fundraising efforts have improved its financial stability, further bolstering Evaxion's capacity to expand its vaccine pipeline and drive value creation in both the oncology and infectious disease sectors.

Bears say

Evaxion AS is positioned in the oncology sector with an AI-Immunology platform; however, its focus on ERV-targeting in tumors with low mutation burden presents a significant risk due to limited efficacy outcomes historically associated with this approach. The company's ability to deliver successful treatments in this challenging segment remains uncertain, raising concerns regarding its long-term financial viability and growth potential. Additionally, the historical performance of checkpoint inhibitors and neoantigen vaccines in such tumors may further jeopardize investor confidence and future revenue generation.

EVAX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 4 analysts, EVAX has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.